In this study conducted in Australia and the United Kingdom, we estimated that about 18% of people with a CDKN2A mutation would develop melanoma by the age of 50 years, and about 50% would develop melanoma by age 80 years. These lifetime risks are substantially higher than the risk of melanoma for the general population. Contrary to the known strong link between sunlight exposure and melanoma risk for the general population, people who carry a CDKN2A mutation appear to have the same lifetime risk of melanoma irrespective of the amount of sunlight to which they are exposed. (By Dr. Anne E Cust, http://jmg.bmj.com/content/early/2011/02/15/jmg.2010.086538.abstract?papetoc= )